Indalpine (INN, BAN) (brand name Upstène; developmental code name LM-5008) is an selective serotonin reuptake inhibitor (SSRI) class drug that was briefly marketed. It was discovered in 1977 by the pharmacologists Le Fur and Uzan at Pharmuka, a small French pharmaceutical firm, who credit Baron Shopsin and his colleagues at NYU-Bellevue/NYU School of Medicine in New York with providing the basis for their work. They were particularly influenced by the series of \"synthesis inhibitor studies\" carried out by Shopsin's team during the early to mid 70's, and in particular, the clinical report by Shopsin et al. (1976) relating to PCPA's rapid reversal of antidepressant response to tranylcypromine in depressed patients. This led to an understanding of the role of the monoamine neurotransmitter serotonin (5-hydroxytryptamine, or 5HT) in the therapeutic effects of the available tricyclic and MAOI class antidepressants. The studies led to widespread recognition of a serotonin hypothesis of depression, contradicting theories that promoted the role of norepinephrine.

CAS：63758-79-2
中文别名：3-(2-(4-哌啶)乙基)-1H-吲哚;
英文别名：EINECS 264-445-4;Lipstene;INDALPINE;LM 5008;
分子式：C15H20N2
分子量：228.333
精确质量：228.163
Psa：27.82
Logp：3.4289

UNII：V35562QSVT

密度：1.07 g/cm3
沸点：405.1ºC at 760 mmHg
闪点：198.8ºC
折射率：1.595

海关编码：2933990090
危险品运输编码：UN 3249
危险类别：6.1(b)
包装等级：III